CClinicalTrials.gg
CompletedNCT06377163Updated Jun 11, 2024

Bacterial Pathogens Associated With Community-acquired Pneumonia in Children

An observational study in Children Chest Infection, sponsored by Delta University for Science and Technology. Completed at 1 site in Egypt. Open to participants aged 28 Days to 10 Years. Per ClinicalTrials.gov, last updated 2024-06-11.

Sponsored by Delta University for Science and Technology · Observational

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
100
Ages
28 Days to 10 Years
Sex
All
01

Study summary

Pediatric community acquired pneumonia (CAP) is one of the most common reasons for hospital admission, there is no reliable way of distinguishing the causative organism based on clinical features.

This study examined common pathogens of community-acquired pneumonia from 28 days up to 10 years in Dakahlia Governorate.

02

Conditions studied

  • Children Chest Infection

Browse trials for

03

In context

Pneumonia

2,044 studies on the registry are indexed under Pneumonia; 283 are open to participants now.

This study's enrollment of 100 is below the median of 203 across 688 observational studies indexed under Pneumonia.

Browse Pneumonia studies →

Lead sponsor

Delta University for Science and Technology is the lead sponsor of 82 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
28 Days to 10 Years
Sexes eligible
All
Sampling method
Probability sample

Study population

A representative sample of 100 participants was taking by simple random sampling technique from children diagnosed to have community acquired pneumonia from Al Mansoura university hospital and Mansura International Hospital.

Inclusion criteria

  • Infants and children aged 28 days to ten years (male and female sexes).
  • Patients diagnosed with community-acquired pneumonia.
  • Pneumonia was diagnosed if the patient fulfilled has fever (temperature ≥38.3° C), Fast breathing (40 breaths per minute if the child is 1 year up to 10 years old), respiratory distress (tachypnea, retractions) and chest indrawing and cyanosis with compatible chest x-ray findings.

Exclusion criteria

Exclusion criteria:

  • Neonates
  • Children more than 10 years
  • Hospital acquired pneumonia
  • Chronic lung disease, immunodeficiency and other congenital anomalies
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
100 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Complete blood count

    From each participant, a sample of 4 ml of fresh venous blood was collected from the peripheral vein by the sterile venipuncture technique \& drawn into a vacuumed purple top tube containing an anticoagulant. It was performed using a fully automated hematology analyzer. This test measures the amounts and sizes of red blood cells, hemoglobin, white blood cells, and platelets. It will be aggregated to arrive at one report. Hemoglobin is usually reported in units of grams per liter, or grams per deciliter. The analyzer counts red blood cells, reporting the result in units of 106 cells per microliter of blood or 1012 cells per liter, and measures their average size, which is called the mean cell volume and expressed in femtoliters or cubic micrometers. The total white blood cell count is usually reported in cells per microliter of blood, or 109 cells per liter. The platelet count can be reported in units of cells per microliter of blood, 103 cells per microliter, or 109 cells per liter.

    Time frame: At the baseline evaluation

  2. C-reactive protein (CRP)

    It was measured quantitatively in human serum by Beckman-Coulter AU Analyzers (USA). Sample preparation: 2 ml of blood in a sterile tube was centrifuged, then used immediately for CRP. C-reactive protein (CRP) is an annular (ring-shaped) pentameric protein found in blood plasma whose circulating concentrations rise in response to inflammation. Traditional CRP measurement only detected CRP in the range of 10 to 1,000 mg/L, whereas high-sensitivity CRP (hs-CRP) detects CRP in the range of 0.5 to 10 mg/L.

    Time frame: At the baseline evaluation

  3. Blood culture and sensitivity on admission

    It was done using the BD Bactec 9050 Blood Culture System (USA, Catalog No. 445800) instrument. A culture was considered positive if any organism was identified.

    Time frame: At the baseline evaluation

  4. Gastric lavage culture or sputum culture on admission

    It was inserted through the nose and down the stomach after nebulization with hypertonic saline at 5% for 10 seconds. Suction was applied for up to 15 seconds to collect the swallowed sputum in a sterile container. A culture was considered positive if any organism was identified.

    Time frame: At the baseline evaluation

07

Study locations

1 site
  • Amira Hussin Mohammed
    Gamasa, 35712, Egypt
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 11, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06377163
Lead sponsor
Delta University for Science and Technology
Responsible party
Amira Hussin Hussin Mohammed (Assistant professor at faculty of physical therapy, Delta University for Science and Technology) — Principal investigator
First posted
Apr 22, 2024
Start date
Jan 1, 2021
Primary completion
Aug 31, 2021
Completion
Aug 31, 2021
Last update
Jun 11, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion